Mining of Respiratory System Toxicity Risk Signals for Fulvestrant Based on the Tianjin Adverse Reaction Monitoring Center and the FDA Adverse Event Reporting System Database. [PDF]
Hosp PharmWang M, Han Q, Jiang Y, Liang G, Yang F.
europepmc +1 more source
PIK3CA mutation testing and alpelisib use in metastatic breast cancer: a real-world data set. [PDF]
Acta OncolDrakenberg Danese MB +4 more
europepmc +1 more source
Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. [PDF]
CellsHuang Z +10 more
europepmc +1 more source
Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study. [PDF]
Breast Cancer ResZou +8 more
europepmc +1 more source
Molecular Profiling and Targeted Therapeutic Strategies in Breast Cancer: Clinical Integration of HER2, CDK4/6, and PI3K Inhibition with Trastuzumab, Abemaciclib and Alpelisib. [PDF]
J Clin MedKawczak P, Bączek T.
europepmc +1 more source
Efficacy and Mechanisms of CDK4/6 Inhibitors in Breast Cancer: Advancing Targeted Therapeutic Strategies. [PDF]
Oncol ResPatwekar M +5 more
europepmc +1 more source
Mutant p53 binds and controls estrogen receptor activity to drive endocrine resistance in ovarian cancer. [PDF]
Genes DevShao C +14 more
europepmc +1 more source